Mayne Pharma Group Balance Sheet Health
Financial Health criteria checks 5/6
Mayne Pharma Group has a total shareholder equity of A$454.2M and total debt of A$31.6M, which brings its debt-to-equity ratio to 7%. Its total assets and total liabilities are A$1.1B and A$689.0M respectively.
Key information
7.0%
Debt to equity ratio
AU$31.64m
Debt
| Interest coverage ratio | n/a |
| Cash | AU$149.28m |
| Equity | AU$454.19m |
| Total liabilities | AU$688.99m |
| Total assets | AU$1.14b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: HG6's short term assets (A$460.6M) exceed its short term liabilities (A$313.9M).
Long Term Liabilities: HG6's short term assets (A$460.6M) exceed its long term liabilities (A$375.1M).
Debt to Equity History and Analysis
Debt Level: HG6 has more cash than its total debt.
Reducing Debt: HG6's debt to equity ratio has reduced from 36.5% to 7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HG6 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: HG6 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 49.3% each year